TY - JOUR
T1 - Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension
AU - Pandey, Ambarish
AU - Raza, Fayez
AU - Velasco, Alejandro
AU - Brinker, Stephanie
AU - Ayers, Colby
AU - Das, Sandeep R.
AU - Morisky, Donald E.
AU - Halm, Ethan A.
AU - Vongpatanasin, Wanpen
N1 - Publisher Copyright:
Copyright © 2015 American Society of Hypertension. All rights reserved.
PY - 2015
Y1 - 2015
N2 - The Morisky Medication Adherence Scale (MMAS-8) is a questionnaire developed for screening of non-adherence in patients with several chronic conditions, including uncomplicated hypertension. However, its accuracy in predicting non-adherence in patients with apparent treatment-resistant hypertension (a-TRH) is not known. Accordingly, we performed a retrospective study in 47 patients with a-TRH who had completed the eight-item MMAS during the initial clinic visit. Non-adherence was defined as presence of undetected serum levels of at least one prescribed antihypertensive drug by therapeutic drug monitoring. We found that 26% of patients were considered to have low adherence score (<6), while the actual prevalence of non-adherence was 51% by therapeutic drug monitoring. Sensitivity of the MMAS-8 was 26% (95% confidence interval, 10.3%-48.4%) with specificity of 75% (95% confidence interval, 53.3%-90.2%). By multivariate analysis, the MMAS-8 score was not an independent predictor of non-adherence, while certain clinical parameters such as heart rate were found to be independent predictors of non-adherence. Our study suggested limited accuracy of the MMAS-8 in detecting medication non-adherence in a-TRH. J Am Soc Hypertens 2015;9(6):420-426.
AB - The Morisky Medication Adherence Scale (MMAS-8) is a questionnaire developed for screening of non-adherence in patients with several chronic conditions, including uncomplicated hypertension. However, its accuracy in predicting non-adherence in patients with apparent treatment-resistant hypertension (a-TRH) is not known. Accordingly, we performed a retrospective study in 47 patients with a-TRH who had completed the eight-item MMAS during the initial clinic visit. Non-adherence was defined as presence of undetected serum levels of at least one prescribed antihypertensive drug by therapeutic drug monitoring. We found that 26% of patients were considered to have low adherence score (<6), while the actual prevalence of non-adherence was 51% by therapeutic drug monitoring. Sensitivity of the MMAS-8 was 26% (95% confidence interval, 10.3%-48.4%) with specificity of 75% (95% confidence interval, 53.3%-90.2%). By multivariate analysis, the MMAS-8 score was not an independent predictor of non-adherence, while certain clinical parameters such as heart rate were found to be independent predictors of non-adherence. Our study suggested limited accuracy of the MMAS-8 in detecting medication non-adherence in a-TRH. J Am Soc Hypertens 2015;9(6):420-426.
KW - Blood pressure control
KW - Self reported adherence
KW - Serum drug levels
UR - http://www.scopus.com/inward/record.url?scp=84942897240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942897240&partnerID=8YFLogxK
U2 - 10.1016/j.jash.2015.04.004
DO - 10.1016/j.jash.2015.04.004
M3 - Article
C2 - 26051923
AN - SCOPUS:84942897240
SN - 1933-1711
VL - 9
SP - 420-426.e2
JO - Journal of the American Society of Hypertension
JF - Journal of the American Society of Hypertension
IS - 6
ER -